Cogent Biosciences Inc Stock News

Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in cash, sufficient to fund operations into late 2026 WALTHAM, Mass. and BOULDER, Colo.

WALTHAM, Mass. and BOULDER, Colo.

Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics

WALTHAM, Mass. and BOULDER, Colo.

65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo.

• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 •  APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 •  Top-line results from PEAK trial in 2 nd -line GIST patients expected by end of 2025 •  $312 million sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2...

WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced an upcoming poster for bezuclastinib at the 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in San Diego, CA, February 28-March 3, ...

Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.